Literature DB >> 12651053

Pulmonary function in primary pulmonary hypertension.

Xing-Guo Sun1, James E Hansen, Ronald J Oudiz, Karlman Wasserman.   

Abstract

OBJECTIVES: The study was done to ascertain the degree to which abnormalities in resting lung function correlate with the disease severity of patients with primary pulmonary hypertension (PPH).
BACKGROUND: Patients with PPH are often difficult to diagnose until several years after the onset of symptoms. Despite the seriousness of the disorder, the diagnosis of PPH is often delayed because it is unsuspected and requires invasive measurements. Although PPH often causes abnormalities in resting lung function, these abnormalities have not been shown to be statistically significant when correlated with other measures of PPH severity.
METHODS: Resting lung mechanics and diffusing capacity for carbon monoxide DL(CO) were assessed in 79 patients whose findings conformed to the classical diagnostic criteria of PPH and who had no evidence of secondary causes of pulmonary hypertension. These findings were correlated with severity of disease as assessed by cardiac catheterization, New York Heart Association (NYHA) class, and cardiopulmonary exercise testing.
RESULTS: When PPH patients were first evaluated at our referral clinic, the DL(CO) and lung volumes were decreased in approximately three-quarters and one-half, respectively. The decreases in DL(CO), and to a lesser extent lung volumes, correlated significantly with decreases in peak oxygen uptake (reflecting maximum cardiac output), peak oxygen pulse (reflecting maximum stroke volume), and anaerobic threshold (reflecting sustainable exercise capacity) and higher NYHA class.
CONCLUSIONS: Patients with PPH commonly have abnormalities in lung mechanics and DL(CO) levels that correlate significantly with disease severity. These measurements can be useful in evaluating patients with unexplained dyspnea and fatigue.

Entities:  

Mesh:

Year:  2003        PMID: 12651053     DOI: 10.1016/s0735-1097(02)02964-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  43 in total

Review 1.  [Consensus recommendations of the Pulmonary Arterial Hypertension Study Group of the Austrian Society of Lung Diseases and Tuberculosis].

Authors:  Rolf Ziesche
Journal:  Wien Klin Wochenschr       Date:  2003-05-30       Impact factor: 1.704

Review 2.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

3.  Pulmonary hypertension in a stable community-based COPD population.

Authors:  Vadim Fayngersh; Fotios Drakopanagiotakis; F Dennis McCool; James R Klinger
Journal:  Lung       Date:  2011-08-04       Impact factor: 2.584

4.  More on idiopathic pulmonary arterial hypertension with a low diffusing capacity.

Authors:  Karen M Olsson; Jan Fuge; Katrin Meyer; Tobias Welte; Marius M Hoeper
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

5.  Spirometry, Static Lung Volumes, and Diffusing Capacity.

Authors:  Carlos A Vaz Fragoso; Hilary C Cain; Richard Casaburi; Patty J Lee; Lynne Iannone; Linda S Leo-Summers; Peter H Van Ness
Journal:  Respir Care       Date:  2017-07-11       Impact factor: 2.258

6.  End-Tidal Carbon Dioxide as a Prognostic Feature in Pulmonary Arterial Hypertension.

Authors:  Caitlin E Welch; Evan L Brittain; Alexander L Newman; Ivan M Robbins; Meredith E Pugh; John H Newman; Anna R Hemnes
Journal:  Ann Am Thorac Soc       Date:  2017-06

7.  Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension.

Authors:  Anastasia Anthi; Roberto F Machado; Maria L Jison; Angelo M Taveira-Dasilva; Lewis J Rubin; Lori Hunter; Christian J Hunter; Wynona Coles; James Nichols; Nilo A Avila; Vandana Sachdev; Clara C Chen; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2007-03-22       Impact factor: 21.405

8.  [Update pulmonary arterial hypertension : Definitions, diagnosis, therapy].

Authors:  N Sommer; M J Richter; K Tello; F Grimminger; W Seeger; H A Ghofrani; H Gall
Journal:  Internist (Berl)       Date:  2017-09       Impact factor: 0.743

9.  Utility of FVC/DLCO ratio to stratify the risk of mortality in unselected subjects with pulmonary hypertension.

Authors:  Lacedonia Donato; Carpagnano Giovanna Elisiana; Galgano Giuseppe; Schino Pietro; Correale Michele; Natale Daniele Brunetti; Ventura Valentina; Di Biase Matteo; Foschino Barbaro Maria Pia
Journal:  Intern Emerg Med       Date:  2016-11-25       Impact factor: 3.397

10.  2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.

Authors:  Chih-Hsin Hsu; Wan-Jing Ho; Wei-Chun Huang; Yu-Wei Chiu; Tsu-Shiu Hsu; Ping-Hung Kuo; Hsao-Hsun Hsu; Jia-Kan Chang; Chin-Chang Cheng; Chao-Lun Lai; Kae-Woei Liang; Shoa-Lin Lin; Hsao-Hsun Sung; Wei-Chuan Tsai; Ken-Pen Weng; Kai-Sheng Hsieh; Wei-Hsian Yin; Shing-Jong Lin; Kuo-Yang Wang
Journal:  Acta Cardiol Sin       Date:  2014-09       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.